Capricor Therapeutics (NASDAQ:CAPR) Issues Earnings Results

Capricor Therapeutics (NASDAQ:CAPR) announced its quarterly earnings data on Monday. The biotechnology company reported ($0.54) EPS for the quarter, meeting the consensus estimate of ($0.54), Zacks reports.

Capricor Therapeutics Stock Performance

Shares of NASDAQ CAPR traded down $0.37 during midday trading on Monday, hitting $5.56. 3,831,050 shares of the company’s stock traded hands, compared to its average volume of 1,837,837. The firm has a fifty day moving average of $6.57 and a 200 day moving average of $8.38. Capricor Therapeutics has a 1 year low of $5.43 and a 1 year high of $20.75. The stock has a market capitalization of $254.19 million, a price-to-earnings ratio of -3.39 and a beta of 0.57.

Institutional Trading of Capricor Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. raised its position in Capricor Therapeutics by 39.5% in the first quarter. Goldman Sachs Group Inc. now owns 411,141 shares of the biotechnology company’s stock worth $3,902,000 after acquiring an additional 116,373 shares during the period. Jump Financial LLC increased its stake in shares of Capricor Therapeutics by 42.6% in the 2nd quarter. Jump Financial LLC now owns 232,536 shares of the biotechnology company’s stock worth $2,309,000 after purchasing an additional 69,515 shares in the last quarter. Marshall Wace LLP bought a new position in Capricor Therapeutics in the 2nd quarter worth $796,000. Rhumbline Advisers raised its holdings in Capricor Therapeutics by 7.3% in the 2nd quarter. Rhumbline Advisers now owns 53,450 shares of the biotechnology company’s stock worth $531,000 after purchasing an additional 3,636 shares during the period. Finally, Legal & General Group Plc lifted its position in Capricor Therapeutics by 8.4% during the second quarter. Legal & General Group Plc now owns 41,273 shares of the biotechnology company’s stock valued at $410,000 after purchasing an additional 3,205 shares in the last quarter. 21.68% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Alliance Global Partners restated a “buy” rating on shares of Capricor Therapeutics in a research note on Monday, July 14th. Roth Capital lowered their price target on Capricor Therapeutics from $31.00 to $12.00 and set a “buy” rating for the company in a research report on Monday, July 14th. HC Wainwright reissued a “buy” rating and set a $24.00 price objective on shares of Capricor Therapeutics in a research report on Thursday, September 25th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Capricor Therapeutics in a report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $22.25.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.